Next Article in Journal
NSAIDs, Opioids, Cannabinoids and the Control of Pain by the Central Nervous System
Next Article in Special Issue
Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway
Previous Article in Journal
The Role of Non-Steroidal Anti-Inflammatory Drugs in Renal Colic
Previous Article in Special Issue
Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
Open AccessReview

Prospects for the Use of ATR Inhibitors to Treat Cancer

Division of Oncology Research, College of Medicine, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(5), 1311-1334; https://doi.org/10.3390/ph3051311
Received: 31 March 2010 / Revised: 12 April 2010 / Accepted: 19 April 2010 / Published: 28 April 2010
(This article belongs to the Special Issue Protein Kinase Inhibitors)
ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use. View Full-Text
Keywords: Replication checkpoint; ATR; ATM; chemotherapy; Chk1 Replication checkpoint; ATR; ATM; chemotherapy; Chk1
Show Figures

Figure 1

MDPI and ACS Style

Wagner, J.M.; Kaufmann, S.H. Prospects for the Use of ATR Inhibitors to Treat Cancer. Pharmaceuticals 2010, 3, 1311-1334.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop